Clinical Trial Update: Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis [Phase 3]

View source ↗

Summary

Phase III long-term, open-label extension study of 0.1% tacrolimus ophthalmic suspension in vernal keratoconjunctivitis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Conjunctivitis
• Keratoconjunctivitis
• Vernal Keratoconjunctivitis

Drugs mentioned

• Tacrolimus ophthalmic suspension 0.1% (tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Keratoconjunctivitis, Conjunctivitis | Phase 3 | Status: COMPLETED